{"id":"cilgavimab","rwe":[{"pmid":"41806221","year":"2026","title":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","finding":"","journal":"British journal of haematology","studyType":"Clinical Study"},{"pmid":"41723474","year":"2026","title":"Epidemiological and economic impact of pre-exposure prophylaxis with targeted immunotherapies for COVID-19 among immunosuppressed patients in Argentina.","finding":"","journal":"Cost effectiveness and resource allocation : C/E","studyType":"Clinical Study"},{"pmid":"41700320","year":"2026","title":"Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.","finding":"","journal":"The Journal of infectious diseases","studyType":"Clinical Study"},{"pmid":"41638347","year":"2026","title":"Clinical outcomes of immunocompromised patients administered tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: Real-world experience in Taiwan.","finding":"","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","studyType":"Clinical Study"},{"pmid":"41637692","year":"2026","title":"Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling.","finding":"","journal":"CPT: pharmacometrics & systems pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"J06BD03","category":"atc"},{"label":"Active","category":"status"},{"label":"COVID-19","category":"indication"},{"label":"AstraZeneca AB","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"AstraZeneca","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CILGAVIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:13.040056+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:18.277671+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:12:13.112945+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CILGAVIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:18.721360+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Spike glycoprotein blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:19.772102+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650258/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:19.423107+00:00"}},"allNames":["cilgavimab","cilgavimab (genetical recombination)","AZD1061","COV2-2130","AZD-1061"],"offLabel":[],"synonyms":["cilgavimab","cilgavimab (genetical recombination)","AZD1061","COV2-2130","AZD-1061"],"timeline":[{"date":"2022-03-25","type":"positive","source":"DrugCentral","milestone":"EMA approval (AstraZeneca AB)"},{"date":"2022-08-30","type":"positive","source":"DrugCentral","milestone":"PMDA approval (AstraZeneca K.K.)"}],"approvals":[{"date":"2022-03-25","orphan":false,"company":"AstraZeneca AB","regulator":"EMA"},{"date":"2022-08-30","orphan":false,"company":"AstraZeneca K.K.","regulator":"PMDA"}],"ecosystem":[{"indication":"COVID-19","otherDrugs":[{"name":"bamlanivimab","slug":"bamlanivimab","company":"Eli Lilly and Company"},{"name":"casirivimab","slug":"casirivimab","company":"Regeneron Pharmaceuticals, Inc."},{"name":"etesevimab","slug":"etesevimab","company":"Eli Lilly and Company"},{"name":"imdevimab","slug":"imdevimab","company":"Regeneron Pharmaceuticals, Inc."}],"globalPrevalence":null}],"mechanism":{"modality":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"Cilgavimab is a monoclonal antibody that targets an unknown epitope on the SARS-CoV-2 spike protein, preventing viral entry into host cells through a mechanism that is not fully understood."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5684","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CILGAVIMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CILGAVIMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:02:24.716655","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:21.030329+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"palivizumab","drugSlug":"palivizumab","fdaApproval":"1998-06-19","relationship":"same-class"},{"drugName":"ansuvimab","drugSlug":"ansuvimab","fdaApproval":"2020-12-21","relationship":"same-class"},{"drugName":"casirivimab","drugSlug":"casirivimab","fdaApproval":"2020-11-21","relationship":"same-class"},{"drugName":"imdevimab","drugSlug":"imdevimab","fdaApproval":"2020-11-21","relationship":"same-class"},{"drugName":"nirsevimab","drugSlug":"nirsevimab","fdaApproval":"2023-07-17","relationship":"same-class"}],"genericName":"cilgavimab","indications":{"approved":[{"name":"COVID-19","source":"DrugCentral","snomedId":840539006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"palivizumab","brandName":"palivizumab","genericName":"palivizumab","approvalYear":"1998","relationship":"same-class"},{"drugId":"ansuvimab","brandName":"ansuvimab","genericName":"ansuvimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"casirivimab","brandName":"casirivimab","genericName":"casirivimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"imdevimab","brandName":"imdevimab","genericName":"imdevimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"nirsevimab","brandName":"nirsevimab","genericName":"nirsevimab","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07473986","phase":"","title":"REAl LIfe\" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-07-08","conditions":["SARS-CoV-2 Omicron Variants"],"enrollment":88,"completionDate":"2024-12-31"},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":["COVID-19"],"enrollment":3800,"completionDate":"2027-01"},{"nctId":"NCT05281601","phase":"PHASE1","title":"AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":["SARS-CoV-2"],"enrollment":46,"completionDate":"2024-04-16"},{"nctId":"NCT05648110","phase":"PHASE2,PHASE3","title":"Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-16","conditions":["COVID-19, SARS-CoV-2"],"enrollment":3882,"completionDate":"2025-02-11"},{"nctId":"NCT05780437","phase":"PHASE3","title":"AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-10","conditions":["COVID-19"],"enrollment":1455,"completionDate":"2023-06-09"},{"nctId":"NCT05216588","phase":"","title":"Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-01-26","conditions":["COVID-19","Immunocompromised Host"],"enrollment":149,"completionDate":"2024-10-31"},{"nctId":"NCT05712096","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-09","conditions":["SARS-CoV-2","COVID-19"],"enrollment":4000,"completionDate":"2023-05-30"},{"nctId":"NCT04625725","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-21","conditions":["COVID-19"],"enrollment":5197,"completionDate":"2023-12-08"},{"nctId":"NCT05166421","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-30","conditions":["Corona Virus Disease"],"enrollment":224,"completionDate":"2023-07-19"},{"nctId":"NCT05184062","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-12-03","conditions":["Coronavirus Disease 2019 (COVID-19)"],"enrollment":272,"completionDate":"2023-05-06"},{"nctId":"NCT05667116","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness at UPMC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-01-09","conditions":["SARS-CoV-2, COVID-19"],"enrollment":4232,"completionDate":"2023-07-24"},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":["COVID-19"],"enrollment":120,"completionDate":"2024-06-17"},{"nctId":"NCT05375760","phase":"PHASE2","title":"A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-06-09","conditions":["Coronavirus Disease 2019 (COVID-19)"],"enrollment":251,"completionDate":"2023-10-04"},{"nctId":"NCT04507256","phase":"PHASE1","title":"AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":["COVID-19"],"enrollment":60,"completionDate":"2021-10-19"},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":["Corona Virus Infection"],"enrollment":1552,"completionDate":"2023-09-25"},{"nctId":"NCT05569408","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in DoD Health System","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-08-10","conditions":["COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease"],"enrollment":4724,"completionDate":"2023-12-22"},{"nctId":"NCT05663957","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in the VA Health System","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-01-04","conditions":["SARS-CoV-2, COVID-19"],"enrollment":5814,"completionDate":"2023-09-01"},{"nctId":"NCT04518410","phase":"PHASE2,PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":["Coronavirus","Covid19"],"enrollment":4044,"completionDate":"2023-06-20"},{"nctId":"NCT05461378","phase":"","title":"PREP (Pre-Exposure Prophylaxis) of COVID-19","status":"COMPLETED","sponsor":"Ghady Haidar","startDate":"2022-07-26","conditions":["Immuno-Deficiency","COVID-19"],"enrollment":138,"completionDate":"2024-01-29"},{"nctId":"NCT06156982","phase":"","title":"An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-12-06","conditions":["COVID-19"],"enrollment":397,"completionDate":"2024-01-09"},{"nctId":"NCT05465876","phase":"PHASE2","title":"Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL","status":"WITHDRAWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-10","conditions":["Chronic Lymphocytic Leukemia","COVID-19"],"enrollment":0,"completionDate":"2025-10"},{"nctId":"NCT05847140","phase":"","title":"A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2022-06-27","conditions":["Pregnancy","Pregnant Women","Pregnancy Outcome"],"enrollment":0,"completionDate":"2024-01-31"},{"nctId":"NCT05803395","phase":"","title":"Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2023-09-12","conditions":["Chronic Lymphocytic Leukemia","Indolent B-Cell Non-Hodgkin Lymphoma","COVID-19"],"enrollment":954,"completionDate":"2024-09"},{"nctId":"NCT04625972","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-02","conditions":["COVID-19"],"enrollment":1131,"completionDate":"2022-07-25"},{"nctId":"NCT05321394","phase":"PHASE3","title":"Non-inferiority Trial on Treatments in Early COVID-19","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2022-03-07","conditions":["COVID-19"],"enrollment":536,"completionDate":"2023-10-29"},{"nctId":"NCT05438498","phase":"PHASE3","title":"Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2","status":"TERMINATED","sponsor":"MediMergent, LLC","startDate":"2022-06-03","conditions":["SARS-CoV-2 Infection"],"enrollment":550,"completionDate":"2023-06-30"},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":["Covid19"],"enrollment":2753,"completionDate":"2023-07-14"},{"nctId":"NCT05982704","phase":"PHASE4","title":"Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19","status":"UNKNOWN","sponsor":"City Clinical Hospital No.52 of Moscow Healthcare Department","startDate":"2022-08-18","conditions":["Coronavirus Infections"],"enrollment":82,"completionDate":"2023-11-01"},{"nctId":"NCT04723394","phase":"PHASE3","title":"Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":["COVID-19"],"enrollment":910,"completionDate":"2022-10-19"},{"nctId":"NCT05437289","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-10-09","conditions":["Coronavirus Disease 2019 (COVID-19)","Healthy Volunteer"],"enrollment":61,"completionDate":"2023-01-16"},{"nctId":"NCT05629923","phase":"","title":"EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2022-02-01","conditions":["COVID-19 Pandemic","Transplant-Related Disorder"],"enrollment":306,"completionDate":"2022-11-30"},{"nctId":"NCT05234398","phase":"","title":"TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2022-02","conditions":["Solid Organ Transplant Recipients"],"enrollment":0,"completionDate":"2023-08"},{"nctId":"NCT05439044","phase":"","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-01","conditions":["Immunocompromised Patients"],"enrollment":4000,"completionDate":"2022-12-31"},{"nctId":"NCT04896541","phase":"PHASE1","title":"Phase I Double-blind, Placebo-controlled Study of AZD7442","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-16","conditions":["COVID-19"],"enrollment":40,"completionDate":"2022-06-14"}],"_emaApprovals":[{"date":"2022-03-25","status":"Authorised","company":"AstraZeneca AB"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"40136","NDDF":"018904","UNII":"1KUR4BN70F","VANDF":"4041037","INN_ID":"11777","RXNORM":"2587306","UMLSCUI":"C5432263","chemblId":"CHEMBL4650258","ChEMBL_ID":"CHEMBL4650258","KEGG_DRUG":"D11994","DRUGBANK_ID":"DB16393","IUPHAR_LIGAND_ID":"11329","MESH_SUPPLEMENTAL_RECORD_UI":"C000714149"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"AstraZeneca","relationship":"Original Developer"},{"period":"2022","companyName":"AstraZeneca K.K.","relationship":"PMDA Licensee"}],"publicationCount":369,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J06BD03","allCodes":["J06BD03"]},"biosimilarFilings":[],"originalDeveloper":"AstraZeneca AB","recentPublications":[{"date":"2026 Mar 10","pmid":"41806221","title":"Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.","journal":"British journal of haematology"},{"date":"2026 Feb 21","pmid":"41723474","title":"Epidemiological and economic impact of pre-exposure prophylaxis with targeted immunotherapies for COVID-19 among immunosuppressed patients in Argentina.","journal":"Cost effectiveness and resource allocation : C/E"},{"date":"2026 Feb 17","pmid":"41700320","title":"Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.","journal":"The Journal of infectious diseases"},{"date":"2026 Apr","pmid":"41638347","title":"Clinical outcomes of immunocompromised patients administered tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: Real-world experience in Taiwan.","journal":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"},{"date":"2026 Feb","pmid":"41637692","title":"Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling.","journal":"CPT: pharmacometrics & systems pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CILGAVIMAB","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2022-08-30T00:00:00.000Z","mah":"AstraZeneca K.K.","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:21.030329+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}